Sight Sciences Inc (SGHT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $601.92M
Last updated: Nov 17, 2026 at 11:05 AM ET
Sight Sciences Inc (SGHT) Earnings: Report Dates and Results
Sight Sciences (SGHT) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Sight Sciences reported EPS of -$0.12, in line with the -$0.12 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SGHT has an expected report date of Mar 2, 2027.
SGHT Earnings Call
The latest SGHT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, SGHT beat 11, missed 10 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $24.92M, up 25.2% from $19.91M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.12 | -$0.12 | -$0.15 - -$0.08 | 0.00% | In line | N/A | 6 | N/A | Nov 4, 2026 | $24.92M |
| Jun 30, 2026 | -$0.08 | -$0.15 | -$0.18 - -$0.07 | +46.67% | Beat | N/A | 5 | 1 up, 0 down | Aug 5, 2026 | $23.39M |
| Mar 31, 2026 | -$0.24 | -$0.20 | -$0.21 - -$0.19 | -20.00% | Miss | N/A | 3 | 3 up, 0 down | May 6, 2026 | $19.70M |
| Dec 31, 2025 | -$0.08 | -$0.15 | -$0.24 - -$0.09 | +47.68% | Beat | N/A | 5 | 1 up, 0 down | Mar 4, 2026 | $20.39M |
| Sep 30, 2025 | -$0.16 | -$0.26 | -$0.34 - -$0.13 | +38.46% | Beat | N/A | 5 | 3 up, 1 down | Nov 6, 2025 | $19.91M |
| Jun 30, 2025 | -$0.23 | -$0.25 | -$0.32 - -$0.21 | +8.00% | Beat | N/A | 6 | 3 up, 0 down | Aug 7, 2025 | $19.56M |
| Mar 31, 2025 | -$0.28 | -$0.23 | -$0.30 - -$0.19 | -21.74% | Miss | N/A | 3 | 0 up, 3 down | May 8, 2025 | $17.51M |
| Dec 31, 2024 | -$0.23 | -$0.18 | -$0.24 - -$0.11 | -30.68% | Miss | N/A | 4 | 2 up, 0 down | Mar 5, 2025 | $19.07M |
| Sep 30, 2024 | -$0.22 | -$0.21 | -$0.31 - -$0.11 | -4.76% | Miss | N/A | 7 | 0 up, 0 down | Nov 7, 2024 | $20.16M |
| Jun 30, 2024 | -$0.25 | -$0.30 | -$0.32 - -$0.25 | +16.67% | Beat | N/A | 6 | 0 up, 0 down | Aug 1, 2024 | $21.37M |
| Mar 31, 2024 | -$0.29 | -$0.28 | -$0.35 - -$0.21 | -3.57% | Miss | N/A | 6 | 0 up, 0 down | May 2, 2024 | $19.27M |
| Dec 31, 2023 | -$0.22 | -$0.32 | -$0.44 - -$0.20 | +31.25% | Beat | N/A | 5 | 0 up, 0 down | Mar 7, 2024 | $18.75M |
| Sep 30, 2023 | -$0.27 | -$0.33 | -$0.40 - -$0.22 | +18.18% | Beat | N/A | 6 | 0 up, 0 down | Nov 7, 2023 | $20.01M |
| Jun 30, 2023 | -$0.30 | -$0.34 | -$0.42 - -$0.27 | +11.76% | Beat | N/A | 7 | 0 up, 0 down | Aug 3, 2023 | $23.47M |
| Mar 31, 2023 | -$0.35 | -$0.39 | -$0.45 - -$0.31 | +10.26% | Beat | N/A | 7 | 0 up, 0 down | May 4, 2023 | $18.82M |
| Dec 31, 2022 | -$0.35 | -$0.42 | -$0.48 - -$0.38 | +16.67% | Beat | N/A | 7 | 0 up, 0 down | Mar 13, 2023 | $20.54M |
| Sep 30, 2022 | -$0.46 | -$0.46 | -$0.49 - -$0.43 | 0.00% | In line | N/A | 7 | 0 up, 0 down | Nov 10, 2022 | $18.68M |
| Jun 30, 2022 | -$0.50 | -$0.42 | -$0.49 - -$0.30 | -19.05% | Miss | N/A | 5 | 0 up, 0 down | Aug 11, 2022 | $17.23M |
| Mar 31, 2022 | -$0.49 | -$0.40 | -$0.46 - -$0.35 | -22.50% | Miss | N/A | 4 | 1 up, 0 down | May 10, 2022 | $14.88M |
| Dec 31, 2021 | -$0.34 | -$0.39 | -$0.44 - -$0.37 | +12.82% | Beat | N/A | 4 | 0 up, 0 down | Mar 24, 2022 | $14.69M |
| Sep 30, 2021 | -$0.43 | -$0.37 | -$0.41 - -$0.34 | -16.22% | Miss | N/A | 3 | 2 up, 0 down | Nov 10, 2021 | $13.10M |
| Jun 30, 2021 | -$1.83 | -$1.72 | -$1.83 - -$0.33 | -6.40% | Miss | N/A | 2 | N/A | Jul 15, 2021 | $12.54M |
| Mar 31, 2021 | -$1.29 | -$0.35 | N/A | -268.57% | Miss | N/A | N/A | N/A | Jun 2, 2021 | $8.63M |
| Dec 31, 2020 | -$2.57 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $8.99M |
| Dec 31, 2019 | -$1.94 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.75, after -$0.99 the year before. It was -$1.94 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.75 | N/A |
| Dec 31, 2024 | -$0.99 | N/A |
| Dec 31, 2023 | -$1.14 | N/A |
| Dec 31, 2022 | -$1.80 | N/A |
| Dec 31, 2021 | -$3.89 | N/A |
| Dec 31, 2020 | -$2.57 | N/A |
| Dec 31, 2019 | -$1.94 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,900 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,931 | 12 | |
| 2026Q2 | Jun 30, 2026 | 5,426 | 11 | |
| 2026Q1 | Mar 31, 2026 | 5,761 | 11 | |
| 2025Q4 | Dec 31, 2025 | 5,337 | 11 | |
| 2025Q3 | Sep 30, 2025 | 6,295 | 11 | |
| 2025Q2 | Jun 30, 2025 | 5,471 | 10 | |
| 2025Q1 | Mar 31, 2025 | 7,084 | 11 | |
| 2024Q4 | Dec 31, 2024 | 8,923 | 11 |
2026Q3 Earnings Call
Opening remarks
Hannah Jeffrey Investor Relations Thank you for participating in today's call. Presenting today are Sight Sciences Co-Founder and Chief Executive Officer, Paul Badawi, and Chief Financial Officer, Jim Rodberg. Also in attendance is Sight Sciences' Chief Operating Officer, Ali Bauerlein. Earlier today, Sight Sciences released financial results for the third quarter ended September 30, 2026, raised its revenue guidance and maintained its adjusted operating expense guidance for the full year 2026. A copy of the press release is available on our website at investors.sightsciences.com. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements within the meaning of federal securities laws. These statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially from projected results due to a number of risks and uncertainties. For a discussion of risks and other factors that may affect the company's future financial results and business, please refer to the earnings release issued prior to this call and the company's SEC filings. We undertake no obligation to publicly update or revise any forward-looking statements, except as required by law. Also on this call, management refers to certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, including adjusted operating expenses. We believe these non-GAAP financial measures are important indicators of the company's operating performance because they exclude items that are unrelated to and may not be indicative of its core operating results. See our earnings release for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, as well as additional information about our reliance on non-GAAP financial measures. I'll now turn the call over to Paul.
Paul Badawi Co-Founder and CEO Thanks, Hannah. Good afternoon, and thank you for joining us. We are extremely proud of our results again this quarter, where we reported record revenue of $24.9 million, growing 25% year-over-year. This marks our third consecutive quarter of double-digit growth and second consecutive quarter of 20% growth or greater. IDE revenue continues to scale rapidly and reached another record quarter with revenue of $3.9 million, and IG continued its momentum and grew 7% to $21 million. Notably, we delivered this high-growth performance while both investing in our growth drivers and significantly improving our cash burn, highlighting the operating leverage in our commercial model. Based on our strong results and outlook, we are raising our full-year 2026 revenue guidance while maintaining our adjusted operating expense guidance. At Sight Sciences, we are focused on delivering minimally invasive technologies that address the underlying cause of two of the most common anterior segment diseases, glaucoma and dry eye disease.
Frequently Asked Questions About SGHT
When is Sight Sciences's next earnings date?
Sight Sciences's next earnings report is expected for Mar 2, 2027.
Did SGHT beat earnings estimates last quarter?
Sight Sciences reported EPS of -$0.12 for the quarter ended Sep 30, 2026, in line with the -$0.12 estimate.
What EPS do analysts expect from SGHT next quarter?
The consensus EPS estimate for Sight Sciences for the quarter ending Dec 31, 2026 is -$0.14 from 9 analysts, with estimates from -$0.17 to -$0.08.
How often does SGHT beat earnings estimates?
Sight Sciences beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +8.55%.
SGHT pages: Overview, Earnings, Forecast, Financials, Competitors